FDA Regulatory and Compliance Risks: Solutions in Life Sciences Transactions

Please join us for a webinar for in-house counsel, business development leads, and private equity and venture capital investors focusing on life sciences transactions.

The life sciences industry is heavily regulated and complex with unique legal and business challenges that present both substantial risk and upside. Arnold & Porter partner Hemmie Chang and senior associate Phil DeFedele will discuss how to potentially mitigate and address major FDA regulatory, compliance, and business risks in different life sciences transactions, including:

• Minimizing business risks for pre-commercial assets/targets
• Post-signing/pre-closing risk mitigation
• Regulatory and compliance considerations for integration
• Managing on-going investigations and enforcement

Whether you are focused on life sciences M&A or licensing deals, this program will provide you with insights on how to navigate these complex regulatory and business issues.